Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.81% |
| 2 | Technology | 15.51% |
| 3 | Consumer Discretionary | 11.84% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3326
Avalon Holdings
AWX
$9.94M
| $243K | ﹤0.01% |
88,310
-10,000
| -10% | -$26.9K |
|
|
APLT
3327
DELISTED
Applied Therapeutics
APLT
| $242K | ﹤0.01% |
317,978
-16,311
| -5% | -$12.9K |
|
3328
Sutro Biopharma
STRO
$416M
| $242K | ﹤0.01% |
2,990
-18,600
| -86% | -$1.29M |
|
3329
Verastem
VSTM
$516M
| $242K | ﹤0.01% |
50,082
-13,616
| -21% | -$66.8K |
|
|
GHSI
3330
DELISTED
Guardion Health Sciences, Inc. Common Stock
GHSI
| $242K | ﹤0.01% |
33,415
-1,064
| -3% | -$8.52K |
|
|
ONCT
3331
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $242K | ﹤0.01% |
12,090
-36,900
| -75% | -$735K |
|
|
HARP
3332
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $242K | ﹤0.01% |
33,297
-14,807
| -31% | -$125K |
|
3333
Business First Bancshares
BFST
$1.04B
| $241K | ﹤0.01% |
10,900
-7,283
| -40% | -$167K |
|
3334
Cousins Properties
CUZ
$5.06B
| $240K | ﹤0.01% |
9,500
-359,831
| -97% | -$8.78M |
|
3335
KraneShares Bosera MSCI China A 50 Connect Index ETF
KBA
$147M
| $240K | ﹤0.01% |
+9,400
| New | +$274K |
|
|
SWKH
3336
DELISTED
SWK Holdings
SWKH
| $240K | ﹤0.01% |
17,163
-379
| -2% | -$5.58K |
|
|
PTRS
3337
DELISTED
Partners Bancorp Common Stock
PTRS
| $240K | ﹤0.01% |
27,100
+600
| +2% | +$5.32K |
|
3338
IBEX
IBEX
$487M
| $239K | ﹤0.01% |
+9,600
| New | +$217K |
|
3339
Invesco S&P SmallCap 600 Revenue ETF
RWJ
$2.11B
| $239K | ﹤0.01% |
6,600
-9,600
| -59% | -$349K |
|
|
AMOV
3340
DELISTED
America Movil SAB de CV
AMOV
| $239K | ﹤0.01% |
13,253
-1,000
| -7% | -$18.3K |
|
3341
Broadway Financial
BYFC
$98.5M
| $238K | ﹤0.01% |
29,412
-9,477
| -24% | -$77.5K |
|
3342
Urban One Class A
UONE
$23.8M
| $238K | ﹤0.01% |
5,230
-3,339
| -39% | -$180K |
|
3343
OppFi
OPFI
$836M
| $236K | ﹤0.01% |
115,100
+100
| +0.1% | +$225 |
|
3344
Energy Services of America
ESOA
$286M
| $235K | ﹤0.01% |
91,300
+35,000
| +62% | +$96.3K |
|
|
SOHO
3345
DELISTED
Sotherly Hotels
SOHO
| $235K | ﹤0.01% |
129,914
-63,100
| -33% | -$126K |
|
|
AMTI
3346
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $235K | ﹤0.01% |
560,700
-118,600
| -17% | -$119K |
|
3347
Eltek
ELTK
$61.4M
| $234K | ﹤0.01% |
56,823
-16,892
| -23% | -$65.8K |
|
|
ARAV
3348
DELISTED
Aravive, Inc. Common Stock
ARAV
| $234K | ﹤0.01% |
177,513
-192,316
| -52% | -$246K |
|
3349
Skillful Craftsman
EDTK
$15.1M
| $233K | ﹤0.01% |
161,900
-8,400
| -5% | -$8.92K |
|
3350
Lisata Therapeutics
LSTA
$10.2M
| $233K | ﹤0.01% |
92,122
-8,800
| -9% | -$32.3K |
|
Similar funds
Renaissance Technologies's Q4 2022 Portfolio in Review
As of Q4 2022, Renaissance Technologies held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Renaissance Technologies added most to Apple in Q4 2022, an estimated $839M increase.
- Renaissance Technologies's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Renaissance Technologies fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Renaissance Technologies's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Renaissance Technologies opened 626 new positions and closed 524 in Q4 2022.
- Renaissance Technologies's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.